Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
News|Articles|April 15, 2014
- Pharmaceutical Technology-04-15-2014
- Volume 2014 eBook
- Issue 1
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
Author(s)Adeline Siew, PhD
Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.
Advertisement
The increasing prevalence and high cost of medication errors have prompted regulators and manufacturers to look into the role of product design in ensuring the safe and correct use of medicines. Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.
Articles in this issue
over 12 years ago
Continuous Manufacturing for Solid-Dosage Drug Productionover 12 years ago
Using Modular Systems in Solid-Dosage Manufacturingover 12 years ago
Advances in Hot-Melt Extrusion Manufacturingover 12 years ago
Selection of Excipients in Generic FormulationsAdvertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5